Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
ConclusionsContrary to previously published studies, our study established head-to-head comparisons of effectiveness and treatment-related costs of first-line EGFR-TKIs. Our findings suggest afatinib was the most cost-effective option among the three EGFR-TKIs.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva